Clinical experience with the prevention of Rh-isoimmunization: a historical comparative analysis.
Clinical experience with prevention of Rh-immunization is reviewed. The pathogenesis of hemolytic disease and the chemistry of prophylaxis is explained. The factors which effect antigenic expression are delineated. The clinical indications for prevention of AMIS are reviewed. International data pertaining to Rhesonativ are presented from postpartum trials and antepartum trials. A protocol for antepartum administration of anti-Rh immunoglobulin is given.
D000939:Epitopes; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007518:Isoantibodies / Q000276:immunology*; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System / Q000276:immunology*
D000939:Epitopes; D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System